Document is current

Article History

Received: 31 July 2025

Accepted: 2 April 2026

First Online: 26 May 2026

Declarations

:

: Vivek Subbiah reports participating in advisory boards for Aadi Biosciences, AbbVie, Bayer, Illumina, Jazz Pharmaceuticals, Labcorp, Loxo Oncology/Eli Lilly, Novartis, Pfizer, Regeneron, Relay Therapeutics, and Roche; and received payment for educational events from Clinical Care Options, LLC. Martin Dietrich reports speaking/services other than consulting from Amgen, AstraZeneca, Bayer, BeOne Oncology, Blueprint Medicines, Boehringer Ingelheim, Bristol Myers Squibb, Caris LifeSciences, Daiichi Sankyo, Eli Lilly & Co., EMD Serono, Epizyme, Foundation Medicine, G1 Therapeutics, Genentech, Gilead Pharmaceuticals, Janssen Pharmaceuticals, Mirati Therapeutics, Myriad, Novartis, Pfizer, Puma, Regeneron, Sanofi Genzyme, Stemline Oncology, and Takeda; consulting for Amgen, AstraZeneca, Bayer, BeOne Oncology, Blueprint Medicines, Boehringer Ingelheim, Bristol Myers Squibb, Caris LifeSciences, Daiichi Sankyo, Eli Lilly & Co., EMD Serono, Epizyme, Foundation Medicine, G1 Therapeutics, Genentech, Gilead Pharmaceuticals, Janssen Pharmaceuticals, Mirati Therapeutics, Myriad, Novartis, Nuvation Bio, Pfizer, Puma, Regeneron, Sanofi Genzyme, Stemline Oncology, and Takeda; and ownership of CrossBridge Therapeutics, LLC. Xiuning Le reports consulting/advisory fees from AbbVie, Abion, ArriVent, AstraZeneca, Bayer, BlossomHill, Blueprint Medicines, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly & Co., EMD Serono (Merck KGaA), Hengrui Therapeutics, Janssen Pharmaceuticals, Novartis, Regeneron, Sensei Biotherapeutics, Spectrum Pharmaceuticals, SystImmune, Taiho, and Teligene; and research funding to the institution from ArriVent, Boehringer Ingelheim, Dizal, Eli Lilly & Co., EMD Serono, Janssen Pharmaceuticals, Regeneron, Takeda, Teligene, and ThermoFisher.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: The authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship of this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

: Vivek Subbiah, Martin Dietrich, and Xiuning Le were involved in conceptualization and development of the content within this podcast episode, and approved the final version to be submitted.